AndroGel Sales Data
| Rank 35 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows AndroGel U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 35 ( 1) |
$351,737 | 5.47% | 1,563 | -1.76% |
| Q3 2013 | 34 ( 2) |
$333,485 | -3.42% | 1,591 | -2.99% |
| Q2 2013 | 36 (1) |
$345,297 | -0.84% | 1,640 | -2.79% |
| Q1 2013 | 37 (1) |
$348,205 | 0.49% | 1,687 | -40.11% |
| Q4 2012 | 36 (1) |
$346,491 | -0.34% | 2,817 | -15.96% |
| Q3 2012 | 37 (7) |
$347,674 | 6.38% | 3,352 | -4.66% |
| Q2 2012 | 44 (3) |
$326,838 | 4.81% | 3,516 | -13.78% |
| Q1 2012 | 47 (6) |
$311,850 | 11.20% | 4,078 | 4.43% |
| Q4 2011 | 53 (3) |
$280,432 | 5.44% | 3,905 | -4.80% |
| Q3 2011 | 50 (1) |
$265,966 | -5.89% | 4,102 | -8.93% |
| Q2 2011 | 49 (7) |
$282,613 | 6.52% | 4,504 | 93.39% |
| Q1 2011 | 56 | $265,323 | n/a | 2,329 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
